參考文獻(xiàn)/References:
[1] Williamson S C, Metcalf R L, Trapani F, et al. Vasculogenic mimicry in small cell lung cancer[J]. Nat Commun,2016,7: 13322.
[2] Hendrix M J, Seftor E A, Seftor R E, et al. Tumor cell vascular mimicry: Novel targeting opportunity in melanoma[J]. Pharmacol Ther,2016,159: 83-92.
[3] Seftor R E, Hess A R, Seftor E A, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise[J]. Am J Pathol, 2012, 181(4): 1115-1125.
[4] Ding J, Jia X, Zuo B, et al. A novel monoclonal antibody targeting a novel epitope of VE cadherin inhibits vasculogenic mimicry of lung cancer cells[J]. Oncol Rep, 2018, 39(6): 2837-2844.
[5] Kim T R, Cho E W, Paik S G, et al. Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy[J]. FEBS Lett, 2012, 586(4): 303-309.
[6] Park B R, Lee S A, Moon S M, et al. Anthricin-induced cas-pase-dependent apoptosis through IGF1R/PI3K/AKT pathway inhibition in A549 human non-small lung cancer cells[J]. Oncol Rep, 2018, 39(6): 2769-2776.
[7] Srivastava A K, Wang Y, Huang R, et al. Human genome meeting 2016: Houston, TX, USA. 28 February-2 March 2016[J]. Hum Genomics, 2016,10(Suppl 1): 12.
[8] Spiliopoulos K, Peschos D, Batistatou A, et al. Vasculogenic mimicry: lessons from melanocytic tumors[J]. In Vivo, 2015, 29(3): 309-317.
[9] Maniotis A J, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739-752.
[10] Frisch C M, Zimmermann K, Zilleβen P, et al. Non-small cell lung cancer cell survival crucially depends on functional insulin receptors[J]. Endocr Relat Cancer, 2015, 22(4): 609-621.
[11] Hess A R, Seftor E A, Seftor R E, et al. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase(MMP)and MMP-2 activity during melanoma cell vasculogenic mimicry[J]. Cancer Res, 2003, 63(16): 4757-4762.
[12] Li Y, Sun B, Zhao X, et al. MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer[J]. J Cell Mol Med, 2017, 21(12): 3741-3751.
[13] Zhao S, Qiu Z, He J, et al. Insulin-like growth factor receptor 1(IGF1R)expression and survival in non-small cell lung cancer patients: a meta-analysis[J]. Int J Clin Exp Pathol, 2014, 7(10): 6694-704.
[14] Gest C, Mirshahi P, Li H, et al. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets[J]. Cancer Lett, 2012, 317(2): 207-217.
相似文獻(xiàn)/References:
[1]林清華 吳聯(lián)平 劉加夫 陳友軒
齊春能 林玉瓊 黃小紅 鄭 靜.晚期非小細(xì)胞肺癌患者胸水液基細(xì)胞學(xué)蠟塊中新抗體D5F3檢測的臨床價(jià)值[J].福建醫(yī)藥雜志,2019,41(01):3.
LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(03):3.
[2]陳新富 劉 寧 劉加夫.CK19在非小細(xì)胞肺癌淋巴結(jié)微轉(zhuǎn)移中的檢測價(jià)值(附90例分析)[J].福建醫(yī)藥雜志,2020,42(04):6.
CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(03):6.
[3]林 瀟 陳愉生 李鴻茹.查爾森合并癥指數(shù)及簡化合并癥評分對晚期非小細(xì)胞肺癌預(yù)后的影響[J].福建醫(yī)藥雜志,2020,42(05):23.
LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(03):23.
[4]黃陽,陳靜波,林貴山.動(dòng)態(tài)監(jiān)測循環(huán)腫瘤細(xì)胞對寡轉(zhuǎn)移非小細(xì)胞肺癌聯(lián)合治療預(yù)后的價(jià)值[J].福建醫(yī)藥雜志,2023,45(05):8.
HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(03):8.
[5]鐘穎,鄒立,陳聲池.EGFR T790M突變豐度對阿美替尼治療晚期非小細(xì)胞肺癌療效的影響[J].福建醫(yī)藥雜志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(03):17.[doi:10.20148/j.fmj.2024.01.005]